Top Markets
#1 Celer Network Celer Network +49.10%
#2 Gravity Gravity +24.44%
#3 Galxe Galxe +23.88%
#4 ICON ICON +13.39%
#5 MemeCore MemeCore +13.25%
#6 Cartesi Cartesi +12.87%
#7 Zilliqa Zilliqa +10.95%
#8 Genius Genius +10.65%
#9 Ontology Gas Ontology Gas +9.33%
#10 CyberDEX CyberDEX +7.13%
Coin of the day
Celer Network Celer Network
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Peringkat dalam Saham #40225
Fusion Antibodies plc operates as a contract research organization (CRO),... Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
Harga Saham
$0.1559364
Terakhir disinkronkan: 2026-09-18
Kapitalisasi Pasar
$195.17K
Perubahan (1 hari)
6.60%
Perubahan (1 tahun)
-30.91%
Negara
GB
Perdagangan Fusion Antibodies plc (FAB)

Kategori

Healthcare
Laba untuk Fusion Antibodies plc (FAB)
Laba pada Sep 2025 TTM: $-2.06M
Menurut laporan keuangan terbaru dari Fusion Antibodies plc, laba saat ini perusahaan adalah $-2.06M. Pada tahun 2024, perusahaan memperoleh laba sebesar $-2.89M, peningkatan dibandingkan laba tahun 2023 sebesar $-3.53M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Fusion Antibodies plc dari 2013 hingga 2026
Laba pada akhir setiap tahun
Tahun Laba Mengubah
2026 (TTM) $-2.06M -10.23%
2025 $-2.30M -20.56%
2024 $-2.89M -18.12%
2023 $-3.53M 101.40%
2022 $-1.75M 0.58%
2021 $-1.74M 30.88%
2020 $-1.33M -31.84%
2019 $-1.95M 95.89%
2018 $-997.05K -731.20%
2017 $157.96K 304.33%
2016 $39.07K -126.49%
2015 $-147.46K -26.55%
2014 $-200.78K -72.11%
2013 $-719.78K 0.00%
Laba untuk perusahaan serupa atau pesaing
Perusahaan Laba Perbedaan Laba Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -256,061.35%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -94,754.12%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 149,694.82%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 194,783.51%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH